Publications by authors named "John Ingram"
Background: Deroofing and local excision are common clinic-based surgical options for hidradenitis suppurativa. Evidence suggests deroofing may have lower rates of adverse events (AEs), defined as disease recurrence or postsurgical complications.
Objective: This cost-utility analysis evaluates the economic and health-related impacts of clinic-based deroofing vs excision for hidradenitis suppurativa, comparing direct medical costs and quality-adjusted life-years (QALYs).
Aim: To measure the impact of type 1 and 2 diabetes mellitus (T1D and T2D) on the QoL of a person's family members/partner and assess if there is any difference in family impact.
Methods: A cross-sectional study, recruited online through patient support groups, involved UK family members/partners of people with diabetes completing the Family Reported Outcome Measure-16 (FROM-16).
Results: Two hundred and sixty-one family members/partners (mean age = 57.
This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker's Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors.
View Article and Find Full Text PDFIntroduction Hidradenitis suppurativa (HS) is a debilitating, inflammatory skin disorder. Treatment strategies in patients with HS are challenging; real-world evidence in a HS population is warranted for greater disease understanding. The objective of this analysis was to describe real-world treatment patterns and treatment satisfaction in patients with HS.
View Article and Find Full Text PDFIntroduction: Hidradenitis suppurativa (HS) is a painful, inflammatory skin disease associated with a high disease burden and long diagnostic delay. Prevalence estimates of HS vary widely in the literature owing to differing estimation methodologies. This study aimed to apply stepwise algorithms to estimate the prevalence of possible/diagnosed cases of HS in the US.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the real-world effectiveness and safety of three treatments for atopic dermatitis: dupilumab, ciclosporin (CyA), and methotrexate (MTX), using data from the A-STAR register in the UK and Ireland.
- It involved 488 patients (adults and children) and measured treatment outcomes like the Eczema Area and Severity Index (EASI) and quality of life scales over 12 months.
- Results showed that dupilumab and CyA led to faster improvements in skin severity scores and overall patient outcomes compared to MTX, indicating dupilumab is an effective option in managing atopic dermatitis.
Methods for describing and reporting the clinical and histologic characteristics of cutaneous tissue samples from patients with hidradenitis suppurativa (HS) are not currently standardized, limiting clinicians' and scientists' ability to uniformly record, report, and communicate about the characteristics of tissue used in translational experiments. A recently published consensus statement outlined morphological definitions of typical HS lesions, but no consensus has been reached regarding clinical characterization and examination of HS tissue samples. In this study, we aimed to establish a protocol for reporting histopathologic and clinical characteristics of HS tissue specimens.
View Article and Find Full Text PDFArticle Synopsis
- * A systematic review identified 24 peer-reviewed studies using DLQI as a primary measure, involving 198,587 patients across various diseases and interventions, highlighting the diversity of research in dermatology.
- * Most studies focused on systemic drug treatments, particularly biologics, making up a significant percentage of the interventions studied, while also including topical, nonpharmacological, and nontraditional treatments.
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, is being tested as a treatment for moderate-to-severe hidradenitis suppurativa, a condition with limited treatment options.
- The BE HEARD I and II trials were 48-week, randomized, double-blind studies that evaluated the efficacy and safety of various dosing regimens of bimekizumab compared to a placebo in over 1,000 patients.
- Results showed significant improvement in patients receiving bimekizumab every 2 weeks, meeting the primary efficacy goal of at least a 50% reduction in disease symptoms by week 16.
Article Synopsis
- The global burden of hidradenitis suppurativa (HS) is poorly understood due to limited and varying prevalence data, which has been affected by different methodologies and diagnostic approaches.
- The Global Hidradenitis Suppurativa Atlas (GHiSA) aims to accurately determine HS prevalence by using a validated questionnaire for screening, followed by physician validation for positive cases, assessing about 10% of negatives for diagnostic accuracy.
- Currently, GHiSA is conducting prevalence studies in 58 countries to create a comprehensive global prevalence estimate through proportional meta-analysis, allowing for direct international comparisons that were not previously feasible.
Article Synopsis
- Core outcome sets (COSs) for skin diseases are standardized outcomes that should be measured in clinical trials, and the number of COSs is growing globally, highlighting potential overlaps in concepts.
- The study aims to conduct a scoping review to categorize and map all outcomes related to COS initiatives for skin diseases, using databases like PubMed and Embase, and involving stakeholder input.
- The research is funded by the Department of Dermatology at Northwestern University, does not require ethical approval due to the nature of the study, and results will be shared through publications and social media.
Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.
Dermatol Ther (Heidelb)
January 2024
Introduction: Hidradenitis suppurativa (HS) has a profound negative impact on patients' health-related quality of life (HRQoL). Here we summarize the evidence on HRQoL and Patient Reported Outcomes (PROs) in patients with HS in real-world settings by conducting a systematic literature review (SLR) of observational studies.
Methods: Data sources included MEDLINE, Embase & PsycINFO between January 1, 2010 and August 29, 2021, and conference proceedings between 2019 and 2021.
Background: Hidradenitis suppurativa is a chronic inflammatory skin disease characterised by recurrent inflammatory lesions and skin tunnels in flexural sites such as the axilla. Deroofing of skin tunnels and laser treatment are standard hidradenitis suppurativa interventions in some countries but not yet introduced in the United Kingdom.
Objective: To understand current hidradenitis suppurativa management pathways and what influences treatment choices to inform the design of future randomised controlled trials.
Article Synopsis
- There are existing registries for hidradenitis suppurativa (HS) in Europe and the USA, but there is no global standard on the data collected, which complicates international collaboration.
- The goal is to create a core dataset (CDS) for global HS registries covering demographics, comorbidities, clinical findings, patient outcomes, and treatments.
- A Delphi process involving 20 experts from eight countries resulted in a consensus on 48 items to be included in all HS registries, promoting consistent data collection worldwide.
Background: Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but are rarely offered in the UK.
Objectives: To describe current UK HS management pathways and influencing factors to inform the design of future randomized controlled trials (RCTs).
Background: Hidradenitis suppurativa (HS), a chronic skin condition that causes pain and physical dysfunction, can impact significantly on quality of life. Disease-specific tools have been designed to assess the impact of HS on patients, including the HS Symptom Daily Diary (HSSDD), the HS Symptom Questionnaire (HSSQ), and the HS Quality of Life (HiSQOL©) questionnaire, which have been developed into electronic instruments (eHSSDD, eHSSQ, and eHiSQOL©).
Objectives: The objective of this study was to establish the content validity of the electronic version of the HSSDD and HSSQ, and the acceptability and usability of the HSSDD, HSSQ, and HiSQOL©, using concept elicitation and cognitive debriefing interviews.